Price List - Imkeldi - Oncological Agents - Chronic Myelogenous Leukemia.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-25-Q-9103
- Issued by
-
Defense Health Agency
About this file
This is a pricing template spreadsheet for the Department of Defense (DoD) Pharmacy Uniform Formulary focused on Oncological Agents in the Chronic Myelogenous Leukemia subclass. The template provides pricing submission formats for both Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) quotes, with quotes due by January 16, 2025 for consideration at the February 5-6, 2025 DoD P&T Committee Meeting.
The template includes sections for up to 10 newly approved drugs, with pricing scenarios for uniform formulary versus non-formulary status in the Military Treatment Facility & Mail Order venues, as well as Tier 2 versus Tier 3 pricing for TRICARE retail refunds. Manufacturers must provide NDC numbers, drug names, strengths, dosage forms, and package sizes along with their pricing. The template requires pricing terms including Federal Ceiling Price (FCP), non-FAMP discounts, and WAC-based discounts. Prior authorization requirements apply, and step therapy protocols require new patients to try preferred agents before non-preferred options.
View the file
Other files
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 |
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 |
| Formulary Notes | |||
| Class Note(s): PA may apply. |
Step Therapy Addendum: Grandfathering: a prior authorization process, would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process. Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 |
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 |
| Formulary Notes | |||
| Class Note(s): PA may apply. |
Step Therapy Addendum: Grandfathering: a prior authorization process, would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process. Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the February 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 |
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 |
| Formulary Notes | |||
| Class Note(s): PA may apply. |
Step Therapy Addendum: Grandfathering: a prior authorization process, would require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process. Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | February 5-6, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | January 16, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .